Catalogo dei prodotti della ricerca

MARCHETTI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.019
EU - Europa 1.623
AS - Asia 1.022
AF - Africa 56
SA - Sud America 20
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.745
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.943
IT - Italia 600
SG - Singapore 421
IN - India 289
SE - Svezia 269
CN - Cina 255
FI - Finlandia 176
DE - Germania 172
UA - Ucraina 90
CA - Canada 68
IE - Irlanda 48
TG - Togo 46
BG - Bulgaria 45
GB - Regno Unito 42
RU - Federazione Russa 39
FR - Francia 31
BE - Belgio 23
GR - Grecia 23
RO - Romania 21
AR - Argentina 15
NL - Olanda 15
ID - Indonesia 13
TR - Turchia 13
IR - Iran 9
PK - Pakistan 9
ES - Italia 8
MX - Messico 8
CH - Svizzera 5
AU - Australia 4
PL - Polonia 4
LT - Lituania 3
ZA - Sudafrica 3
AT - Austria 2
BR - Brasile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
KZ - Kazakistan 2
MA - Marocco 2
MU - Mauritius 2
SC - Seychelles 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
HK - Hong Kong 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
KR - Corea 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
PE - Perù 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 8.745
Salva come PNG Salva come JPEG
Città #
Fairfield 1.172
Ashburn 498
Woodbridge 474
Seattle 410
Houston 390
Cambridge 338
Wilmington 337
Chandler 328
Singapore 316
Rome 267
Ann Arbor 180
Beijing 173
Princeton 166
Santa Clara 140
Plano 134
Dearborn 130
San Paolo di Civitate 105
Millbury 87
Lawrence 80
Helsinki 71
San Diego 66
Bremen 61
Boston 60
Dublin 48
Lomé 46
Sofia 45
Andover 43
Norwalk 29
Toronto 28
Brussels 22
Jacksonville 22
North York 22
New York 20
Des Moines 19
Fremont 18
Falkenstein 16
Falls Church 15
Redwood City 15
Florence 14
Kunming 14
Federal 13
Jakarta 13
Milan 12
Moscow 12
Boardman 11
Istanbul 11
Mannheim 11
Ottawa 11
Nanjing 9
Phoenix 9
Turin 8
Hefei 7
London 7
Los Angeles 7
Jinan 6
Mexico City 6
Fort Worth 5
Hyderabad 5
Monterotondo 5
Southend 5
Bühl 4
Changsha 4
Gurgaon 4
Hebei 4
San Mateo 4
Valencia 4
Wuhan 4
Bern 3
Chicago 3
Deventer 3
Frankfurt am Main 3
Lyon 3
Nanchang 3
Pomezia 3
Prossedi 3
Redmond 3
Torino 3
Velletri 3
Albany 2
Albuquerque 2
Amsterdam 2
Antalya 2
Athens 2
Baotou 2
Bogotá 2
Calenzano 2
Catanzaro 2
Chicoutimi 2
Cormano 2
Dongguan 2
Fuzhou 2
Karachi 2
Kilburn 2
Laurel 2
Markham 2
Miami 2
Montréal 2
Muizenberg 2
Paola 2
Paris 2
Totale 6.697
Salva come PNG Salva come JPEG
Nome #
Rucaparib. An emerging parp inhibitor for treatment of recurrent ovarian cancer 126
NEOADJUVANT CHEMOTHERAPY FOLLOWED BY RADICAL SURGERY IN PATIENTS AFFECTED BY VAGINAL CARCINOMA 115
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 112
Fertility preservation in gynaecologic cancers 111
Brain metastases from malignant Brenner tumor of the ovary. a case report and a literature review 109
Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis 107
Dose-dense weekly chemotherapy in advanced ovarian cancer: an updated meta-analysis of randomized controlled trials 104
Autologous In Vitro Cultured Vaginal Tissue for Women Subjected to the Abbe-McIndoe Vaginoplasty: A Case Series 103
Bevacizumab in ovarian cancer: state of the art and unanswered questions 101
Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis 101
Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: an evidence-based approach on what women should know 99
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. 96
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 95
Immune check-point in cervical cancer 94
Advances in anti-angiogenic agents for ovarian cancer treatment: the role of trebananib (AMG 386) 91
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients 91
Perivascular epithelioid cell neoplasm (PEComa) of the uterus: a systematic review 91
Comparison of anogenital distance and correlation with vulvo-vaginal atrophy: a pilot study on premenopausal and postmenopausal women 91
Impact of hormone receptor status and Ki-67 expression on disease-free survival in patients affected by high-risk endometrial cancer 89
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis 89
Valutazione del ruolo prognostico dei sottotipi istologici nei carcinomi papilliferi della tiroide con particolare riferimento della variante in sclerosi diffusa. 87
Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis 87
Ixabepilone for the treatment of endometrial cancer 87
PARP inhibition: a promising therapeutic target in ovarian cancer 87
null 85
Solitary gastric recurrence from ovarian carcinoma: A case report and literature review 84
Survival nomograms after curative neoadjuvant chemotherapy and radical surgery for stage IB2-IIIB cervical cancer 84
Chemotherapy in elderly patients with gynecological cancer 83
Surgical treatment of an isolated omental cervical cancer recurrence: Report of a case and review of the literature 83
Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: evaluation of feasibility and morbidity of different surgical techniques 82
Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: a meta-analysis 81
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 80
Cervical cancer: are there potential new targets? An update on preclinical and clinical results 80
A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. 79
null 78
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials 78
Mid-trimester isolated short femur and perinatal outcomes: a systematic review and meta-analysis 78
Brain metastases in patients with EOC: clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 78
CO2 laser therapy of the Bartholin's gland cyst: surgical data and functional short- and long-term results. 77
Cediranib in ovarian cancer. state of the art and future perspectives 77
Management of endometriomas 77
Defective DNA repair mechanisms in prostate cancer: impact of olaparib 76
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms 74
Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy 74
null 72
Role of chemotherapy in the management of vulvar carcinoma 72
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: the MITO-9 study 72
Multiple Bulky Lymph Nodal Metastasis in Microinvasive Cervical Cancer: A Case Report and Literature Review. 71
Screening program in ovarian cancer: a logical step in clinical management? A meta-analysis 70
An unexpected complete remission of advanced intestinal-type vulvar adenocarcinoma after neoadjuvant chemotherapy: a case report and a literature review. 70
null 69
The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. 69
Beyond the beyond: first case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: case report 68
Limits of ¹⁸F-fluorodeoxyglucose positron emission tomography in recurrence diagnosis of borderline ovarian tumor. 68
CO2 Laser Treatment for Bartholin Gland Abscess: Ultrasound Evaluation of Risk Recurrence 67
Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: case report and literature review. 67
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study 66
Corrigendum to “Bartholin gland cancer” (Bartholin gland cancer (2017) 117 (1–11) 66
Imaging strategy in recurrent ovarian cancer: a practical review 66
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series 66
null 65
MODIFIED GLUTEAL FOLD ADVANCEMENT V-Y FLAP FOR VULVAR RECONSTRUCTION AFTER SURGERY FOR VULVAR MALIGNANCIES. 65
Late aortic lymphocele and residual ovary syndrome after gynecological surgery. 65
Complete remission after neoadjuvant chemotherapy of an advanced vulvar cancer patient: A case report 64
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: a single institution retrospective review 64
Olaparib, PARP1 inhibitor in ovarian cancer 63
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study. 62
Effects of neoadjuvant chemotherapy plus radical surgery as front line treatment strategy in patients affected by FIGO stage III cervical cancer 62
Immunotherapy of ovarian cancer: the role of checkpoint inhibitors 62
OP29.03: Identification of parametria by 2D-3D ultrasound in patients with cervical cancer: new perspectives and future applications 62
Metformin reduces maternal weight gain in obese pregnant women: a systematic review and meta‐analysis of two randomized controlled trials 62
Immune check-point in endometrial cancer 62
Isolated contralateral groin relapse in vulvar cancer. 62
Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study 61
Late breast cancer recurrence to the uterine cervix with a review of the literature 61
Epistaxis in Weekly Paclitaxel Regimen: Is it Really Related to Schedule? 60
PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? 60
Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors 60
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. 60
Ovarian cancer long term survivors and their genetic predisposition: a case report 59
Erythropoiesis-stimulating agents in gynecological malignancies: a study-level meta-analysis 59
Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view 59
Bmi is a key prognostic factor in stage iiic-iv ovarian cancer diagnosed prior 65 years old: a 10-year survival analysis 59
Modified gluteal fold advancement V-Y flap for vulvar reconstruction after surgery for vulvar malignancies 58
null 57
null 56
Minimally Invasive Surgical Approach for Treatment of Isolated Endometrial Cancer Recurrence in an Ultra-Morbidly Obese Patient 55
Inguinofemoral Lymphadenectomy: Randomized Trial Comparing Inguinal Skin Access Above or Below the Inguinal Ligament 55
Hormone therapy in oophorectomized BRCA1/2 mutation carriers 54
Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer 54
Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens 54
Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer. Analysis and management of complications in upper abdominal surgery 54
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling 53
null 53
First-line treatment of advanced ovarian cancer: current research and perspectives. 53
From the tailoring of adjuvant treatment to the tailoring of pelvic and aortic lymphadenectomy in stage i endometrial cancer 52
null 52
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 52
null 49
Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers 48
Totale 7.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.703 0 0 0 0 0 358 366 294 264 241 114 66
2020/2021663 67 103 27 42 16 65 11 47 80 91 67 47
2021/20221.346 6 74 142 34 185 55 23 165 95 101 169 297
2022/20231.441 306 299 61 184 135 134 38 66 140 11 50 17
2023/2024731 47 99 19 76 82 85 27 96 4 69 64 63
2024/2025641 39 164 96 48 180 114 0 0 0 0 0 0
Totale 9.326